Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn’s disease: 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment

The prospective RUN-CD registry investigates the effectiveness of ustekinumab (UST) and other biologics in Crohn’s disease (CD) across Germany. Based on data from the registry, this study presents the maintenance phase results of a 12-month real-world-evidence (RWE) comparison of CD patients initiat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bokemeyer, Bernd (VerfasserIn) , Plachta-Danielzik, Sandra (VerfasserIn) , Gilman, Elena (VerfasserIn) , di Giuseppe, Romina (VerfasserIn) , Deppe, Herbert (VerfasserIn) , Mohl, Wolfgang (VerfasserIn) , Teich, Niels (VerfasserIn) , Hoffstadt, Martin (VerfasserIn) , Schweitzer, Axel (VerfasserIn) , von der Ohe, Manfred (VerfasserIn) , Gauss, Annika (VerfasserIn) , Atreya, Raja (VerfasserIn) , Krause, Thomas (VerfasserIn) , Blumenstein, Irina (VerfasserIn) , Hartmann, Petra (VerfasserIn) , Schreiber, Stefan (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: April 2025
In: Journal of Crohn's and Colitis
Year: 2025, Jahrgang: 19, Heft: 4, Pages: 1-13
ISSN:1876-4479
DOI:10.1093/ecco-jcc/jjaf051
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/ecco-jcc/jjaf051
Volltext
Verfasserangaben:Bernd Bokemeyer, Sandra Plachta-Danielzik, Elena Gilman, Romina di Giuseppe, Herbert Deppe, Wolfgang Mohl, Niels Teich, Martin Hoffstadt, Axel Schweitzer, Manfred von der Ohe, Annika Gauss, Raja Atreya, Thomas Krause, Irina Blumenstein, Petra Hartmann, Stefan Schreiber

MARC

LEADER 00000naa a2200000 c 4500
001 1937757897
003 DE-627
005 20251006115250.0
007 cr uuu---uuuuu
008 251006s2025 xx |||||o 00| ||eng c
024 7 |a 10.1093/ecco-jcc/jjaf051  |2 doi 
035 |a (DE-627)1937757897 
035 |a (DE-599)KXP1937757897 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Bokemeyer, Bernd  |e VerfasserIn  |0 (DE-588)1163767964  |0 (DE-627)1028130252  |0 (DE-576)508210852  |4 aut 
245 1 0 |a Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn’s disease  |b 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment  |c Bernd Bokemeyer, Sandra Plachta-Danielzik, Elena Gilman, Romina di Giuseppe, Herbert Deppe, Wolfgang Mohl, Niels Teich, Martin Hoffstadt, Axel Schweitzer, Manfred von der Ohe, Annika Gauss, Raja Atreya, Thomas Krause, Irina Blumenstein, Petra Hartmann, Stefan Schreiber 
246 3 0 |a twelve 
264 1 |c April 2025 
300 |b Illustrationen 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online veröffentlicht: 25. März 2025 
500 |a Gesehen am 06.10.2025 
520 |a The prospective RUN-CD registry investigates the effectiveness of ustekinumab (UST) and other biologics in Crohn’s disease (CD) across Germany. Based on data from the registry, this study presents the maintenance phase results of a 12-month real-world-evidence (RWE) comparison of CD patients initiating new biologic therapies with UST or anti-TNF.After excluding patients using biologics other than UST and anti-TNF and those with missing outcomes, the final sample consisted of 618 CD patients. Clinical remission (CR), defined as a Harvey-Bradshaw Index (HBI) ≤4, was the prespecified endpoint at 12 months. Switching to another biologic therapy was considered an outcome failure. Propensity score adjustment was used to reduce the effect of confounders.The study included 343 CD patients treated with UST and 264 treated with anti-TNF. Over 12 months, the frequency of therapy switches was significantly higher for infliximab (28%) compared with UST (17%) and adalimumab (17%) (P =.045). There was no significant difference in CR rates at 12 months between the UST and anti-TNF groups (65.8% vs 60.0%, P =.262). However, in week-16 responders, CR rates at 12 months were significantly higher with UST (77.6%) versus anti-TNF (65.4%) (P =.041). The change in EQ-VAS (QoL) scores between UST and anti-TNF showed a 5.1-point difference favoring UST (P =.002).In this 12-month RWE comparison, overall CR rates were similar between UST and anti-TNF. However, among week-16 responders, CR rates were significantly higher with UST. Additionally, UST was associated with a significantly greater improvement in QoL compared with anti-TNF. 
700 1 |a Plachta-Danielzik, Sandra  |e VerfasserIn  |4 aut 
700 1 |a Gilman, Elena  |e VerfasserIn  |4 aut 
700 1 |a di Giuseppe, Romina  |e VerfasserIn  |4 aut 
700 1 |a Deppe, Herbert  |e VerfasserIn  |4 aut 
700 1 |a Mohl, Wolfgang  |e VerfasserIn  |4 aut 
700 1 |a Teich, Niels  |e VerfasserIn  |4 aut 
700 1 |a Hoffstadt, Martin  |e VerfasserIn  |4 aut 
700 1 |a Schweitzer, Axel  |e VerfasserIn  |4 aut 
700 1 |a von der Ohe, Manfred  |e VerfasserIn  |4 aut 
700 1 |a Gauss, Annika  |d 1978-  |e VerfasserIn  |0 (DE-588)129331856  |0 (DE-627)393102092  |0 (DE-576)297603523  |4 aut 
700 1 |a Atreya, Raja  |e VerfasserIn  |4 aut 
700 1 |a Krause, Thomas  |e VerfasserIn  |4 aut 
700 1 |a Blumenstein, Irina  |e VerfasserIn  |4 aut 
700 1 |a Hartmann, Petra  |e VerfasserIn  |4 aut 
700 1 |a Schreiber, Stefan  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of Crohn's and Colitis  |d Oxford : Oxford Univ. Press, 2007  |g 19(2025), 4 vom: Apr., Artikel-ID jjaf051, Seite 1-13  |h Online-Ressource  |w (DE-627)546008631  |w (DE-600)2389631-0  |w (DE-576)284748390  |x 1876-4479  |7 nnas  |a Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn’s disease 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment 
773 1 8 |g volume:19  |g year:2025  |g number:4  |g month:04  |g elocationid:jjaf051  |g pages:1-13  |g extent:13  |a Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn’s disease 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment 
856 4 0 |u https://doi.org/10.1093/ecco-jcc/jjaf051  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20251006 
993 |a Article 
994 |a 2025 
998 |g 129331856  |a Gauss, Annika  |m 129331856:Gauss, Annika  |d 910000  |d 910100  |d 50000  |e 910000PG129331856  |e 910100PG129331856  |e 50000PG129331856  |k 0/910000/  |k 1/910000/910100/  |k 0/50000/  |p 11 
999 |a KXP-PPN1937757897  |e 4781233597 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"title":[{"title_sort":"Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn’s disease","subtitle":"12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment","title":"Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn’s disease"}],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"April 2025"}],"recId":"1937757897","type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"546008631","origin":[{"dateIssuedKey":"2007","dateIssuedDisp":"2007-","publisher":"Oxford Univ. Press ; Elsevier","publisherPlace":"Oxford ; Amsterdam [u.a.]"}],"note":["Gesehen am 21.02.15"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn’s disease 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustmentJournal of Crohn's and Colitis","id":{"eki":["546008631"],"zdb":["2389631-0"],"issn":["1876-4479"]},"name":{"displayForm":["European Crohn's and Colitis Organisation"]},"pubHistory":["1.2007 -"],"part":{"year":"2025","text":"19(2025), 4 vom: Apr., Artikel-ID jjaf051, Seite 1-13","volume":"19","issue":"4","pages":"1-13","extent":"13"},"language":["eng"],"title":[{"title":"Journal of Crohn's and Colitis","title_sort":"Journal of Crohn's and Colitis"}]}],"note":["Online veröffentlicht: 25. März 2025","Gesehen am 06.10.2025"],"physDesc":[{"noteIll":"Illustrationen","extent":"13 S."}],"id":{"eki":["1937757897"],"doi":["10.1093/ecco-jcc/jjaf051"]},"name":{"displayForm":["Bernd Bokemeyer, Sandra Plachta-Danielzik, Elena Gilman, Romina di Giuseppe, Herbert Deppe, Wolfgang Mohl, Niels Teich, Martin Hoffstadt, Axel Schweitzer, Manfred von der Ohe, Annika Gauss, Raja Atreya, Thomas Krause, Irina Blumenstein, Petra Hartmann, Stefan Schreiber"]},"person":[{"family":"Bokemeyer","role":"aut","given":"Bernd","display":"Bokemeyer, Bernd"},{"given":"Sandra","role":"aut","display":"Plachta-Danielzik, Sandra","family":"Plachta-Danielzik"},{"family":"Gilman","display":"Gilman, Elena","role":"aut","given":"Elena"},{"family":"di Giuseppe","display":"di Giuseppe, Romina","role":"aut","given":"Romina"},{"family":"Deppe","display":"Deppe, Herbert","given":"Herbert","role":"aut"},{"role":"aut","given":"Wolfgang","display":"Mohl, Wolfgang","family":"Mohl"},{"family":"Teich","role":"aut","given":"Niels","display":"Teich, Niels"},{"family":"Hoffstadt","display":"Hoffstadt, Martin","role":"aut","given":"Martin"},{"given":"Axel","role":"aut","display":"Schweitzer, Axel","family":"Schweitzer"},{"family":"von der Ohe","given":"Manfred","role":"aut","display":"von der Ohe, Manfred"},{"display":"Gauss, Annika","given":"Annika","role":"aut","family":"Gauss"},{"given":"Raja","role":"aut","display":"Atreya, Raja","family":"Atreya"},{"given":"Thomas","role":"aut","display":"Krause, Thomas","family":"Krause"},{"given":"Irina","role":"aut","display":"Blumenstein, Irina","family":"Blumenstein"},{"role":"aut","given":"Petra","display":"Hartmann, Petra","family":"Hartmann"},{"role":"aut","given":"Stefan","display":"Schreiber, Stefan","family":"Schreiber"}]} 
SRT |a BOKEMEYERBCOMPARATIV2025